Source: Annual Congress 2009 - Pathology and immunology of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Polverino, S. Baraldo, G. Turato, E. Bazzan, S. Agostino, G. Girbino, M. Polverino, E. Balestro, A. Papi, P. Maestrelli, C. Santoriello, F. Calabrese, M. Saetta (Cava dei Tirreni, Padova, Messina, Ferrara, Italy). Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients. Eur Respir J 2009; 34: Suppl. 53, 1601

Member's Comments

No comment yet.

Related content which might interest you: Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004 Fas Ligand (FasL) expressed on alveolar lymphocytes (AL) plays role in progression of interstitial lung diseases (ILD) but not in local induction of immune cells apoptosis Source: Eur Respir J 2005; 26: Suppl. 49, 542s Year: 2005 Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly? Year: 2007 Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006 Expression of epidermal growth factor receptor (EGFR) in the bronchial epithelium of patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Expression of angiogenic growth factors and stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis in idiopathic pulmonary fibrosis: a lung tissue study Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Increased expression of a proliferation-inducing ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: A possible link between COPD and lung cancer? Source: International Congress 2016 – Mechanisms of disease Year: 2016 Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Expression of interferon regulatory factor 8 in human lung dendritic cell subsets Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Steroid-induced BAL lymphocyte (L-BAL) apoptosis as prognostic factor in patients with bronchial asthma (AB) Source: Eur Respir J 2005; 26: Suppl. 49, 281s Year: 2005 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Contribution of genetic polymorphism of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, to the susceptibility and severity of non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008